Medtronic plc (NYSE:MDT) shares are down on Tuesday as the company announced plans to acquire Scientia Vascular, a move aimed at enhancing its neurovascular portfolio.

This decline comes as broader markets are experiencing a downturn, with major indices like the S&P 500 and Nasdaq both in the red.

$550 Million Deal

The acquisition is expected to strengthen Medtronic’s position in the neurovascular space, integrating Scientia’s access and therapeutic solutions.

The acquisition is valued at $550 million, with potential undisclosed earn-out and milestone payments post-acquisition.

Scientia is a private company with approximately 310 employees.

Deal Rationale

Under founder and current chief technology officer John Lippert, the company has developed access products that enable simplicity and access for physicians treating complex neurovascular conditions.

Scientia’s portfolio of guidewires and catheters can be integrated with Medtronic’s existing suite of neurovascular products, strengthening the company’s ability to support physicians across the full procedural workflow.

This acquisition is expected to close in the first half of fiscal 2027. It ...